NLX-112 Shows Safety and Tolerability in Phase 2a Parkinson Trial, Supporting Further Development Louie Pasculli

Published Date: 25 Jan 2026

A phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer mortality continuing to decline, says report

2.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

3.

Financial hardship common in patients with cancer

4.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

5.

Advancing Health in Africa


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot